Table 3.
Results of logistic and linear regressions of the HOPE effect in the matched cohort.
| Effect* | 95% CI | p | |
|---|---|---|---|
| Stage 2–3 acute kidney injury | 0.29 | 0.08–0.86 | 0.024 |
| Severe post-reperfusion syndrome | 0.24 | 0.02–1.11 | 0.069 |
| Early allograft dysfunction | 0.93 | 0.33–2.50 | 0.89 |
| ALT peak (IU/L) | −25 | −326–+276 | 0.87 |
| AST peak (IU/L) | −73 | −699–554 | 0.82 |
| Lactate at the end of LT | 0.05 | −0.68–+0.68 | 0.89 |
| Grade ≥3 complications | 0.91 | 0.16–5.06 | 0.87 |
| Acute rejection | 2.39 | 1.62–3.53 | 0.20 |
| Hospital stay (days) | −2.3 | −9.1–+4.4 | 0.49 |
| ITU stay (days) | 0.13 | −1.5–+1.8 | 0.87 |
| Biliary complications | 1.26 | 0.32–4.95 | 0.70 |
| Anastomotic | |||
| Overall | 1.24 | 0.28–5.49 | 0.76 |
| Symptomatic | 1.52 | 0.51–4.57 | 0.56 |
| Post-transplant cholangiopathy | |||
| Overall | 0.89 | 0.15–5.19 | 0.90 |
| Symptomatic | 0.34 | 0.002–4.41 | 0.45 |
*For dichotomous outcomes (acute kidney injury, post-reperfusion syndrome, early allograft dysfunction and biliary complications) effect represents the odds ratio of the outcome in patients treated with HOPE; for continuous outcomes (ALT and AST peak) effect represents the mean variation of the outcome in treated patients. Abbreviations: HOPE, hypothermic oxygenated machine perfusion; CI, confidence interval; ALT, alanine aminotransferase; AST, aspartate aminotransferase.